← Back to Search

Other

BLU-5937 for Chronic Cough

Phase 3
Recruiting
Research Sponsored by Bellus Health Inc. - a GSK company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Refractory chronic cough (including unexplained chronic cough) for at least one year
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 24
Awards & highlights

Study Summary

This trial tests a new drug for people with a persistent, hard-to-treat cough.

Who is the study for?
Adults with a persistent cough lasting over a year, not explained by other lung conditions like COPD or asthma, can join this study. They must be non-smokers for at least six months and have no recent infections or history of serious illness like cancer within the past five years.Check my eligibility
What is being tested?
The trial is testing BLU-5937, a potential new medication for chronic cough that hasn't responded to other treatments. Participants will either receive BLU-5937 or a placebo (a substance with no active drug) over 24 weeks to compare effectiveness and safety.See study design
What are the potential side effects?
Specific side effects of BLU-5937 are not listed here, but common side effects in trials may include nausea, headache, dizziness, and fatigue. Placebo groups typically experience fewer side effects since they do not contain an active drug.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have had a chronic cough for at least one year that hasn't improved with treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Coughing
Secondary outcome measures
Change from Baseline in Cough Severity Visual Analogue Scale at Week 24
Change from Baseline in the Leicester Cough Questionnaire (LCQ) Total Score at Week 24
Percentage of Participants With a ≥1.3-point Increase From Baseline in Leicester Cough Questionnaire (LCQ) Total Score at Week 24
+2 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: BLU-5937 50 mgExperimental Treatment1 Intervention
BLU-5937 oral dose 50 mg twice a day.
Group II: BLU-5937 25 mgExperimental Treatment1 Intervention
BLU-5937 oral dose 25 mg twice a day.
Group III: PlaceboPlacebo Group1 Intervention
Matching Placebo for BLU-5937 oral dose twice a day.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BLU-5937
2021
Completed Phase 2
~580

Find a Location

Who is running the clinical trial?

Bellus Health Inc. - a GSK companyLead Sponsor
17 Previous Clinical Trials
4,513 Total Patients Enrolled
3 Trials studying Chronic Cough
1,203 Patients Enrolled for Chronic Cough
Bellus Health IncLead Sponsor
15 Previous Clinical Trials
4,447 Total Patients Enrolled
3 Trials studying Chronic Cough
1,203 Patients Enrolled for Chronic Cough

Media Library

BLU-5937 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05600777 — Phase 3
Chronic Cough Research Study Groups: BLU-5937 25 mg, BLU-5937 50 mg, Placebo
Chronic Cough Clinical Trial 2023: BLU-5937 Highlights & Side Effects. Trial Name: NCT05600777 — Phase 3
BLU-5937 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05600777 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the status of BLU-5937 50 mg in regards to FDA approval?

"BLU-5937 50 mg is in Phase 3 of clinical trials, thus there is some evidence of its efficacy and multiple rounds of data affirming its safety; our team at Power rates its safety a 3 on a scale from 1 to 3."

Answered by AI

Does this study allow for elderly participation?

"The patients who meet the age requirements of 18-80 and are eligible for this study. There are 1 studies for patients under the age of 18 and 32 for people over 65."

Answered by AI

Are there still positions available for participants in this experiment?

"The trial, which was originally posted on clinicaltrials.gov on October 1st, 2022, is still recruiting patients."

Answered by AI

How many people have the opportunity to participate in this trial?

"In order to move forward, this study needs 675 individuals that match the pre-specified inclusion criteria. If you are interested, patients can enroll at locations such as Clinical Site Partners, LLC d/b/a CSP Leesburg in Leesburg, Florida and Houston Pulmonary, Sleep, Allergy and Asthma Associates in Cypress, Texas."

Answered by AI

Who else is applying?

What state do they live in?
Illinois
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)
2023. "A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05600777.
~426 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top